Abstract
In the last decade, researchers have searched for predictive surface markers of multipotent mesenchymal stromal/stem cells (MSCs) for ensuring improved therapeutic outcomes following cartilage damage in humans. However, we have achieved only limited progress because of the challenge presented by conflicting data. This commentary provides some evidence to prove a lack of success with current efforts, including an inconsistency in accepted surface markers and chondrogenic potential of MSCs as well as the tissue source–dependent MSC surface markers that correlate with chondrogenic potential. A brief discussion on these disputed topics and perspective about functionally predictive surface markers and standardization of analytic procedures are also highlighted.
Funder
Musculoskeletal Transplant Foundation
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference47 articles.
1. Prevalence of disabilities and associated health conditions among adults--United States, 1999;MMWR Morb Mortal Wkly Rep.,2001
2. Treatment of articular cartilage lesions of the knee.;M Falah;Int Orthop.,2010
3. Mesenchymal stem cell-based therapy for cartilage repair: a review.;H Koga;Knee Surg Sports Traumatol Arthrosc.,2009
4. Multilineage potential of adult human mesenchymal stem cells.;M Pittenger;Science.,1999
5. Marrow stromal cells as stem cells for nonhematopoietic tissues.;D Prockop;Science.,1997
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献